Aberdeen Group plc Sells 4,632 Shares of Becton, Dickinson and Company $BDX

Aberdeen Group plc decreased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 0.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 511,452 shares of the medical instruments supplier’s stock after selling 4,632 shares during the period. Aberdeen Group plc’s holdings in Becton, Dickinson and Company were worth $99,257,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC grew its holdings in Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after acquiring an additional 877 shares during the last quarter. Empowered Funds LLC boosted its position in Becton, Dickinson and Company by 20.4% during the first quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock valued at $1,827,000 after acquiring an additional 1,354 shares during the last quarter. United Bank boosted its holdings in shares of Becton, Dickinson and Company by 23.9% during the 2nd quarter. United Bank now owns 5,149 shares of the medical instruments supplier’s stock worth $887,000 after buying an additional 993 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its holdings in shares of Becton, Dickinson and Company by 9.0% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 15,402 shares of the medical instruments supplier’s stock valued at $2,653,000 after purchasing an additional 1,266 shares during the period. Finally, Arrowstreet Capital Limited Partnership acquired a new stake in Becton, Dickinson and Company in the second quarter valued at approximately $33,993,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, Director Bertram L. Scott sold 953 shares of the company’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total value of $174,027.33. Following the sale, the director directly owned 36,763 shares of the company’s stock, valued at $6,713,291.43. This represents a 2.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Michael David Garrison sold 1,610 shares of the firm’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total value of $334,010.60. Following the transaction, the executive vice president directly owned 12,095 shares of the company’s stock, valued at $2,509,228.70. This represents a 11.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 2,713 shares of company stock worth $536,881. 0.40% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several analysts recently issued reports on BDX shares. TD Cowen lifted their price target on shares of Becton, Dickinson and Company from $183.00 to $189.00 and gave the company a “hold” rating in a research report on Wednesday, February 11th. Royal Bank Of Canada set a $172.00 price objective on shares of Becton, Dickinson and Company in a report on Tuesday, February 10th. Jefferies Financial Group decreased their price objective on Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating for the company in a report on Tuesday, February 10th. Piper Sandler reaffirmed a “neutral” rating and set a $170.00 target price (down from $205.00) on shares of Becton, Dickinson and Company in a research report on Tuesday, February 10th. Finally, Stifel Nicolaus upped their price target on Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Six investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Becton, Dickinson and Company currently has an average rating of “Hold” and a consensus price target of $191.62.

Becton, Dickinson and Company Trading Up 0.0%

Becton, Dickinson and Company stock opened at $154.52 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.58 and a current ratio of 1.05. The firm’s fifty day moving average price is $175.69 and its 200-day moving average price is $186.48. The stock has a market cap of $44.00 billion, a P/E ratio of 25.21, a PEG ratio of 11.20 and a beta of 0.29. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, topping analysts’ consensus estimates of $2.81 by $0.10. The firm had revenue of $4.49 billion during the quarter, compared to analyst estimates of $5.15 billion. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The business’s quarterly revenue was up 1.6% on a year-over-year basis. During the same period in the previous year, the business posted $3.43 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Equities research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company announced that its Board of Directors has authorized a share buyback program on Tuesday, January 27th that allows the company to repurchase $10.00 million in outstanding shares. This repurchase authorization allows the medical instruments supplier to buy up to 0% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s board believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th were given a $1.05 dividend. The ex-dividend date of this dividend was Tuesday, March 10th. This represents a $4.20 annualized dividend and a dividend yield of 2.7%. Becton, Dickinson and Company’s dividend payout ratio is currently 68.52%.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.